

Паспорт

Посуда мерная лабораторная для клинических исследований стеклянная по ТУ 9464-013-52876351-2014

Цилиндры мерные с носиком на стеклянном основании

1. Назначение

Предназначены для отмеривания определенного объема нелетучих жидкостей.

2. Основные технические характеристики

Наименование	Вместимость, см ³	Допустимая погрешность, см ³	Цена деления, см ³	Высота не более, мм
Цилиндр 1-10-2	10	± 0,2	0,2	140
Цилиндр 1-25-2	25	± 0,5	0,5	170
Цилиндр 1-50-2	50	± 1,0	1,0	200
Цилиндр 1-100-2	100	± 1,0	1,0	260
Цилиндр 1-250-2	250	± 2,0	2,0	335
Цилиндр 1-500-2	500	± 5,0	5,0	390
Цилиндр 1-1000-2	1000	± 10,0	10,0	470
Цилиндр 1-2000-2	2000	± 20,0	20,0	570

1. Цилиндры изготовлены по ТУ 9464-013-52876351-2014 в соответствии с техническими требованиями ГОСТ 1770-74.
2. Изготовлены из стекла ХС1 по ГОСТ 21400-75.
3. Исполнение 1 – с носиком, класс точности 2.
4. Буква «Н» в маркировке, обозначает наливной, вымеряемый «по наполнению».

3. Упаковывание, транспортирование и хранение

Упаковка изделий обеспечивает их сохранность при транспортировке. Транспортная упаковка имеет надпись: «Осторожно, стекло». Условия транспортирования изделий - по ГОСТ 15150-69 в крытом транспорте любого вида. Условия хранения - по ГОСТ 15150-69.

4. Требования безопасности

При эксплуатации необходимо соблюдать правила безопасности при работе со стеклянными изделиями. Изделия не должны подвергаться резким ударам в процессе эксплуатации.

5. Сведения об утилизации

Изделия не представляют опасности для окружающей среды, жизни и здоровья людей после окончания срока службы. Порядок утилизации изделий определяется Потребителем.

6. Гарантии изготовителя

Изготовитель: ООО «МиниМедПром», 242600, Россия, Брянская область, г. Дятьково, ул. Ленина, д. 182, корп. 5.

Изготовитель гарантирует соответствие цилиндров мерных с носиком на стеклянном основании требованиям ТУ 9464-013-52876351-2014 и ГОСТ 1770-74 при соблюдении потребителем условий транспортирования, хранения и эксплуатации. Гарантийный срок эксплуатации — 12 месяцев со дня ввода в эксплуатацию.

7. Свидетельство о приемке

Изделия изготовлены в соответствии с действующей технической документацией и признаны годными для эксплуатации.

Начальник ОТК

Грузинцев С.А.



Регистрационное удостоверение № ФСР 2009/05559 от 04.12.2015 г.

Паспорт

Набор реагентов «Масло иммерсионное» по ТУ 9398-011-29508133-2009

Серия	1094	Дата изготовления	10.09.2021 г.
-------	------	-------------------	---------------

1. Назначение

Используется в качестве иммерсионной жидкости для световой и флуоресцентной микроскопии, обладает низким уровнем автофлуоресценции.

2. Технические требования

Наименование показателя	Характеристика и норма по ТУ	Результаты анализа
Органолептические показатели	Прозрачная бесцветная жидкость со слабым желтоватым оттенком	соответствует
Вязкость кинематическая при температуре 20°C, мм ² /с	от 220	1267
Показатель преломления при температуре 20°C	от 1,5150 до 1,5180	1,5154
Коэффициент пропускания масла, %	не менее 70	440 нм-98,8 540 нм-100,0

Иммерсионное масло легко удаляется с поверхности препарата, фронтальной линзы и оправы объектива; инертно к окрашенным и неокрашенным препаратам.

Упаковка – флакон-капельница вместимостью 10,0 мл обеспечивает аккуратное и экономичное нанесение масла на препарат.

Срок годности – 1,5 года с даты изготовления.

3. Транспортирование и хранение

Транспортирование должно проводиться всеми видами крытого транспорта в соответствии с правилами перевозки грузов, действующими на данном виде транспорта. Хранение - в упаковке предприятия-изготовителя в прохладном месте при относительной влажности воздуха не более 80% в местах, защищенных от воздействия прямых солнечных лучей, атмосферных осадков и агрессивных сред в течение всего срока годности.

4. Гарантии изготовителя

Изготовитель гарантирует соответствие качества набора реагентов «Масло иммерсионное» требованиям ТУ 9398-011-29508133-2009 при соблюдении потребителем условий транспортирования, хранения и применения в течение всего срока годности.

Начальник ПТО




Бабич В.А.



ФЕДЕРАЛЬНОЕ АГЕНТСТВО
ПО ТЕХНИЧЕСКОМУ РЕГУЛИРОВАНИЮ И МЕТРОЛОГИИ
СИСТЕМА ДОБРОВОЛЬНОЙ СЕРТИФИКАЦИИ ГОСТ Р
«EAC AUDIT»

РЕГИСТРАЦИОННЫЙ НОМЕР РОСС RU.32028.04EAC1
ОРГАН ПО СЕРТИФИКАЦИИ ООО «ГОРТЕСТ»
РЕГИСТРАЦИОННЫЙ НОМЕР РОСС RU.32028
ИНН 7717616798 ОГРН 1087746489060

Юридический адрес: 109028, Россия, г. Москва, Серебряническая набережная, д. 27,
этаж 4, пом. 1, ком. 17
Телефон: 8 (800) 1000-730, e-mail: info@eacaudit.ru



№003749

СЕРТИФИКАТ СООТВЕТСТВИЯ

Регистрационный номер № 04EAC1.CM.00813

Общество с ограниченной ответственностью «МиниМед»

(наименование лица)

241520, Россия, Брянская область, Брянский район, с. Супонево, ул. Шоссейная, д.17А

(юридический адрес лица)

241520, Россия, Брянская область, Брянский район, с. Супонево, ул. Шоссейная, д.17А

(фактический адрес лица)

ИНН: 3234007127

ОГРН: 1023202138332

НАСТОЯЩИЙ СЕРТИФИКАТ УДОСТОВЕРЯЕТ СООТВЕТСТВИЕ

системы менеджмента качества изделий медицинских Общества с ограниченной ответственностью «МиниМед» требованиям ГОСТ ISO 13485-2017 (ISO 13485:2016) «Изделия медицинские. Системы менеджмента качества. Системные требования для целей регулирования» применительно к Производство лабораторной посуды, медицинских изделий, приборов и принадлежностей, красителей, реагентов и наборов реагентов для in-vitro диагностики

Дата регистрации: 19-03-2019

Срок действия до: 18-03-2022

Руководитель органа
по сертификации:

(подпись)

В. И. Погодин


Председатель
экспертной комиссии:



(подпись)

Е. Д. Курбатова

НАСТОЯЩИЙ СЕРТИФИКАТ ОБЯЗЫВАЕТ ОРГАНИЗАЦИЮ ПОДДЕРЖИВАТЬ СОСТОЯНИЕ ВЫПОЛНЯЕМЫХ РАБОТ В СООТВЕТСТВИИ С ВЫШЕУКАЗАННЫМИ СТАНДАРТАМИ, ЧТО БУДЕТ НАХОДИТЬСЯ ПОД КОНТРОЛЕМ ОРГАНА ПО СЕРТИФИКАЦИИ СИСТЕМЫ ДОБРОВОЛЬНОЙ СЕРТИФИКАЦИИ "EAC AUDIT" И ПОДТВЕРЖДАТЬСЯ ПРИ ПРОХОЖДЕНИИ ЕЖЕГОДНОГО ИНСПЕКЦИОННОГО КОНТРОЛЯ



NSAI

Quality System Approval Certificate

In Vitro Diagnostic Medical Devices Directive 98/79/EC

*The National Standards Authority of Ireland as a duly designated
Notified Body, (identification number 0050), for the purposes of the European Communities
(In Vitro Diagnostics Medical Devices) Regulations (S.I. No. 304 of 2001)*

APPROVES THE QUALITY SYSTEM APPLIED BY

Monobind Inc.

**100 North Pointe Drive
Lake Forest
CA 92630
USA**

For the Product Family

**Total and Free Prostate Specific Antigen (PSA and Free PSA) IVD,
kit, chemiluminescent immunoassay (CLIA) and enzyme
immunoassay (ELISA) and control.**

GMDN Code: 54664, 54669

*On the basis of examination under the requirements of Annex IV, Section 3 of Directive 98/79/EC,
The use of the NSAI Notified Body identification number 0050 in conjunction with CE Marking of
Conformance for this product is hereby authorized.*

Registration Number:	304.1006
Original Approval:	28 October 2011
Last Amended on:	25 August 2021
Remains valid until:	12 July 2023

Signed:

(Signature)
Approved by
Dr Caroline Dore Geraghty
Director, Medical Devices

(Signature)
Approved by
Dr Elaine Darcy
European Medical Device Operations
Manager

**This certificate remains valid on condition that the Approved Quality System is maintained in an adequate and efficacious manner.
Details of the current product range and operational locations included within the scope of this approval can be obtained from NSAI**

National Standards Authority of Ireland, 1 Swift Square, Northwood, Santry, Dublin 9, Ireland.



MEDICAL
DEVICES
ISO 13485:2016
NSAI Certified

DECLARATION OF CONFORMITY

Product Family TOTAL AND FREE PROSTATE SPECIFIC ANTIGEN (PSA and FPSA)

Specific Product Details						
Product Description	Item # ELISA	Item # CLIA	EDMS Code	GMDN ELISA Code	GMDN CLIA Code	Risk Class
Total PSA Test System	2125-300A 2125-300B	2175-300A 2175-300B	12.03.01.32.00	54664	54665	High/ List B
Total PSA Extra Sensitive Test System	8725-300A 8725-300B	8775-300A 8775-300B	12.03.01.32.00	54664	54665	High/ List B
Free PSA Test System	2325-300A 2325-300B	2375-300A 2375-300B	12.03.01.33.00	54668	54669	High/ List B
Cancer VAST Test System	8425-300B 8425-300D 8425-300E	8475-300B 8475-300D 8475-300E	12.03.01.32.00	54664	54665	High/ List B
Multi Ligand Control	ML-300B	ML-300B	12.03.01.32.00	38207	38207	High/ List B

Manufacturer

Name Monobind Inc.
Address 100 North Pointe, Lake Forest, CA 92630
Country United States

Representative

Name CEpartner4U BV,
Address Esdoornlaan 13, 3951DB Maarn
Country The Netherlands
Telephone +31 (0)6 – 516.536.26

Notified Body

Name NSAI
Body ID Number 0050
CE Cert # 304.1006
Registration # NL-CA002-2011-23306

Means of Conformity

Monobind Inc. declares that the product listed is in conformity with the Annex IV, IVD Type List B essential requirements and provisions of Council Directive: 98/79/EC

And is in conformance with the following standards:

EN 13612:2002	EN 15223-1:2016	EN ISO 14971:2019
EN ISO 18113:2011	EN 13641:2002	EN ISO 23640:2015
Under the principles of	EN ISO 13485:2016	

Signature

Place and effective date Monobind Inc. January 30, 2021 revision 04

Signature

A Shatola

Name

Tony Shatola

Title QA Director

DECLARATION OF CONFORMITY

1) Manufacturer (Name, department): **Monobind Inc.**

Address: **100 North Pointe, LAKE FOREST, CA 92630. UNITED STATES**

and

2) European authorized representative: **CEpartner4U BV,**

Address: **ESDOORNLAAN 13, 3951DB MAARN, THE NETHERLANDS;**

(on product labels printed as:

CEpartner4U , ESDOORNLAAN 13, 3951DB MAARN, THE NETHERLANDS. www.cepartner4u.com)

3) Product(s) (name, type or model/batch number, etc.):

Immunoassay products;

AccuBind® ELISA,

AccuLite® CLIA,

QSure® Control,

Instruments

see appendix

4) The product(s) described above is in conformity with:

<u>Document No.</u>	<u>Title</u>
98/79/EC	<i>In vitro</i> Diagnostic Medical Devices Directive

5) Additional information (Conformity procedure, Notified Body, CE certificate, Registration nr., etc.):

Conformity assessment procedure for CE marking: *In vitro* Diagnostic Medical Device Directive, Annex III

Registration nr. : **NL- CA002-22758 and NL- CA002-22762**

Lake Forest, USA; 2021-09-20



(Place & date of issue (yyyy-mm-dd))

Tony Shatola; QA Director, Monobind Inc.
(name, function and signature of manufacturer)

Appendix

Date: 2021-09-20

List of devices.

<i>Device types</i>	<i>Item# AccuBind® ELISA Microwells</i>	<i>Item# AccuLite® CLIA Microwells</i>	<i>Item# QSure® Control</i>	<i>Item# Instru- ment</i>	<i>EDMS code</i>	<i>Risk Class</i>	<i>First date of CE-marking</i>
Allergy & Anemia							
Ferritin Test System	2825-300A 2825-300B	2875-300A 2875-300B			12.07.01.02.00	Low	2005-11-11
Folate Test System	7525-300A 7525-300B	7575-300A 7575-300B			12.07.01.03.00	Low	2010-06-29
Immunoglobulin E (IgE) Test System	2525-300A 2525-300B	2575-300A 2575-300B			12.02.01.02.00	Low	2005-11-11
Transferrin Soluble Receptor (sTfR) Test System	8625-300A 8625-300B	8675-300A 8675-300B			12.07.01.06.00	Low	2010-06-29
Vitamin B-12 (Vit B12) Test System	7625-300A 7625-300B	7675-300A 7675-300B			12.07.02.04.00	Low	2011-09-26
Folate, Vitamin B-12 (Anemia Panel VAST) Test System	7825-300A 7825-300B	7875-300A 7875-300B			12.07.01.00.00	Low	2013-09-16
Autoimmune							
Anti-Cyclic Citrullinated Peptide IgG (Anti-CCP IgG) Test System	12725-300A 12725-300B	12775-300A 12775-300B			12.11.01.90.00	Low	2019-04-03
Anti-Thyroglobulin (Anti-Tg) Test System	1025-300A 1025-300B	1075-300A 1075-300B			12.10.03.04.00	Low	2005-11-11
Anti-Thyropoxidase (Anti-TPO) Test System	1125-300A 1125-300B	1175-300A 1175-300B			12.10.03.01.00	Low	2005-11-11
Bone Metabolism & Growth							
Calcitonin Test System	9325-300A 9325-300B	9375-300A 9375-300B			12.06.03.02.00	Low	2019-04-03
Growth Hormone (hGH) Test System	1725-300A 1725-300B	1775-300A 1775-300B			12.06.04.02.00	Low	2005-11-11
Parathyroid Hormone (PTH) Test System	9025-300A 9025-300B	9075-300A 9075-300B			12.06.03.13.00	Low	2011-09-26
Parathyroid Hormone (PTH) 3rd & 2nd Gen (VAST) Test System	10025-300A 10025-300B	10075-300A 10075-300B			12.06.03.13.00	Low	2019-04-03
25(OH) Vitamin D Total Direct (Vit D-Direct) Test System	7725-300A 7725-300B	7775-300A 7775-300B			12.06.03.10.00	Low	2017-07-05
Cancer Markers							
Alpha-Fetoprotein (AFP) Test System	1925-300A 1925-300B	1975-300A 1975-300B			12.03.90.01.00	Low	2005-11-11
CA-125 Test System	3025-300A 3025-300B	3075-300A 3075-300B			12.03.01.06.00	Low	2005-11-11
CA 15-3 Test System	5625-300A 5625-300B	5675-300A 5675-300B			12.03.01.02.00	Low	2010-06-29
CA 19-9 Test System	3925-300A 3925-300B	3975-300A 3975-300B			12.03.01.03.00	Low	2005-11-11
Carcinoembryonic Antigen (CEA) Test System	1825-300A 1825-300B	1875-300A 1875-300B			12.03.01.31.00	Low	2005-11-11
Next Generation Carcinoembryonic Antigen	4625-300A	4675-300A			12.03.01.31.00	Low	2010-06-29

<i>Device types</i>	<i>Item# AccuBind® ELISA Microwells</i>	<i>Item# AccuLite® CLIA Microwells</i>	<i>Item# QSure® Control</i>	<i>Item# Instru- ment</i>	<i>EDMS code</i>	<i>Risk Class</i>	<i>First date of CE-marking</i>
(CEA-Next Gen) Test System	4625-300B	4675-300B					
Free β-Subunit Human Chorionic Gonadotropin (Free Beta hCG) Test System	2025-300A 2025-300B	2075-300A 2075-300B			12.03.01.90.00	Low	2005-11-11
Cardiac Markers							
CK-MB Test System	2925-300A 2925-300B	2975-300A 2975-300B			12.13.01.02.00	Low	2005-11-11
Digoxin (DIG) Test System	925-300A 925-300B	975-300A 975-300B			12.08.01.01.00	Low	2005-11-11
High Sensitivity CRP (hs-CRP) Test System	3125-300A 3125-300B	3175-300A 3175-300B			12.13.01.90.00	Low	2005-11-11
Myoglobin Test System	3225-300A 3225-300B	3275-300A 3275-300B			12.13.01.05.00	Low	2005-11-11
Troponin I (cTnI) Test System	3825-300A 3825-300B	3875-300A 3875-300B			12.13.01.07.00	Low	2005-11-11
Diabetes							
C-Peptide Test System	2725-300A 2725-300B	2775-300A 2775-300B			12.06.01.01.00	Low	2005-11-11
Insulin Test System	2425-300A 2425-300B	2475-300A 2475-300B			12.06.01.03.00	Low	2005-11-11
Rapid Insulin Test System	5825-300A 5825-300B				12.06.01.03.00	Low	2010-06-29
Insulin - C-Peptide (Diabetes Panel VAST)	7325-300A 7325-300B	7375-300A 7375-300B			12.06.01.03.00	Low	2005-11-11
Endocrine							
ACTH Test System	10625-300	10675-300			12.06.04.01.00	Low	2019-04-03
Aldosterone Test System	10125-300	10175-300			12.06.02.01.00	Low	2019-04-03
Leptin Test System	10925-300	10975-300			12.06.90.17.00	Low	2019-04-03
Fertility & Prenatal							
Anti-Müllerian Hormone (AMH) Test System	9725-300A 9725-300B	9775-300A 9775-300B			12.05.02.16.00	Low	2019-04-03
Folicle Stimulating Hormone (FSH) Test System	425-300A 425-300B	475-300A 475-300B			12.05.01.04.00	Low	2005-11-11
B-Human Chorionic Gonadotropin (hCG) Test System	825-300A 825-300B	875-300A 875-300B			12.05.02.05.00	Low	2005-11-11
B-Human Chorionic Gonadotropin Extended Range (hCG-XR) Test System	8825-300A 8825-300B	8875-300A 8875-300B			12.05.02.05.00	Low	2013-09-16
Rapid B-Human Chorionic Gonadotropin (Rapid hCG) Test System	3325-300A 3325-300B				12.05.02.05.00	Low	2005-11-11
Inhibin A Test System	9525-300A 9525-300B	9575-300A 9575-300B			12.05.01.90.00	Low	2019-04-03
Inhibin B Test System	9625-300A 9625-300B	9675-300A 9675-300B			12.05.01.90.00	Low	2019-04-03
Luteinizing Hormone (LH) Test System	625-300A 625-300B	675-300A 675-300B			12.05.01.05.00	Low	2005-11-11
Pregnancy Associated Plasma Protein – A Mass Units (PAPP-A Mass Units) Test System	12625-300A 12625-300B	12675-300A 12675-300B			12.05.02.10.00	Low	2017-07-05
Prolactin Hormone (PRL) Test System	725-300A 725-300B	775-300A 775-300B			12.05.01.08.00	Low	2005-11-11

<i>Device types</i>	<i>Item# AccuBind® ELISA Microwells</i>	<i>Item# AccuLite® CLIA Microwells</i>	<i>Item# QSure® Control</i>	<i>Item# Instru- ment</i>	<i>EDMS code</i>	<i>Risk Class</i>	<i>First date of CE-marking</i>
Prolactin Hormone Sequential (PRLs) Test System	4425-300A 4425-300B	4475-300A 4475-300B			12.05.01.08.00	Low	2005-11-11
Human Chorionic Gonadotropin (hCG) , Human Prolactin (hPRL), Human Luteinizing Hormone (hLH), Follicle Stimulating Hormone (FSH) (Fertility Panel VAST) Test System	8325-300B 8325-300D 8325-300E	8375-300B 8375-300D 8375-300E			12.05.01.90.00	Low	2006-08-24
Alpha-Fetoprotein (AFP), Human Chorionic Gonadotropin (hCG), Unconjugated Estiol (u-E3) Triple Screen (Triple Screen Panel VAST) Test System	8525-300A 8525-300B	8575-300A 8575-300B			12.05.01.90.00	Low	2010-06-29
Infectious Diseases							
Anti-H. Pylori IgG (H. Pylori Ab IgG) Test System	1425-300A 1425-300B	1475-300A 1475-300B			15.01.04.03.00	Low	2005-11-11
Anti-H. Pylori IgM (H. Pylori Ab IgM) Test System	1525-300A 1525-300B	1575-300A 1575-300B			15.01.04.03.00	Low	2005-11-11
Anti-H. Pylori IgA (H. Pylori Ab IgA) Test System	1625-300A 1625-300B	1675-300A 1675-300B			15.01.04.03.00	Low	2005-11-11
Anti-SARS-CoV-2 (COVID-19) IgG Test System	11925-300A 11925-300B	11975-300A 11975-300B			15.04.80.90.00	Low	2020-08-25
Anti-SARS-CoV-2 (COVID-19) IgM Test System	11725-300A 11725-300B	11775-300A 11775-300B			15.04.80.90.00	Low	2020-08-25
Anti-SARS-CoV-2 (COVID-19) IgA Test System	11825-300A 11825-300B	11875-300A 11875-300B			15.04.80.90.00	Low	2020-08-25
Anti-SARS-CoV-2 (COVID-19) S1-RBD IgG Test System	12025-300A 12025-300B	12075-300A 12075-300B			15.04.80.90.00	Low	2021-09-20
D-Dimer Test System	9225-300A 9225-300B	9275-300A 9275-300B			13.02.05.03.00	Low	2020-08-25
Procalcitonin (PCT) Test System	1425-300A 1425-300B	1475-300A 1475-300B			12.06.90.16.00	Low	2017-07-05
Neonatal							
Neonatal 17OHP (N-17OHP) Test System	5525-300A 5525-300B				12.05.01.07.00	Low	2008-02-01
Neonatal (N-T4) Thyroxine Test System	2625-300A 2625-300B				12.04.01.12.00	Low	2005-11-11
Neonatal TBG (N-TBG) Test System	8925-300A 8925-300B				12.04.01.09.00	Low	2013-09-16
Neonatal TSH (N-TSH) Test System	3425-300A 3425-300B 3425-300D 3425-300E				12.04.01.90.00	Low	2005-11-11
Steroid							
Androstenedione (ANST) Test System	12425-300A 12425-300B	12475-300A 12475-300B			12.05.01.01.00	Low	2021-09-20
Cortisol Test System	3625-300A 3625-300B	3675-300A 3675-300B			12.06.02.04.00	Low	2005-11-11
Dehydroepiandrosterone (DHEA) Test System	7425-300A 7425-300B	7475-300A 7475-300B			12.05.01.02.00	Low	2011-09-26
Dehydroepiandrosterone Sulfate (DHEA-S) Test System	5125-300A 5125-300B	5175-300A 5175-300B			12.05.01.02.00	Low	2010-06-29
Estrone (E1) Test System	10325-300A 10325-300B	10375-300A 10375-300B			12.05.02.04.00	Low	2019-04-03

<i>Device types</i>	<i>Item# AccuBind® ELISA Microwells</i>	<i>Item# AccuLite® CLIA Microwells</i>	<i>Item# QSure® Control</i>	<i>Item# Instru- ment</i>	<i>EDMS code</i>	<i>Risk Class</i>	<i>First date of CE-marking</i>
Estradiol (E2) Test System	4925-300A 4925-300B	4975-300A 4975-300B			12.05.01.03.00	Low	2010-06-29
Unconjugated Estiol (u-E3) Test System	5025-300A 5025-300B	5075-300A 5075-300B			12.05.02.02.00	Low	2010-06-29
Progesterone Test System	4825-300A 4825-300B	4875-300A 4875-300B			12.05.01.06.00	Low	2010-06-29
17-OH Progesterone (17-OHP) Test System	5225-300A 5225-300B	5275-300A 5275-300B			12.05.01.07.00	Low	2010-06-29
17-OH Progesterone SI (17-OHP-SI) Test System	9925-300A 9925-300B	9975-300A 9975-300B			12.05.01.07.00	Low	2010-10-18
Sex Hormone Binding Globulin (SHBG) Test System	9125-300A 9125-300B	9175-300A 9175-300B			12.05.01.09.00	Low	2013-09-16
Testosterone Test System	3725-300A 3725-300B	3775-300A 3775-300B			12.05.01.10.00	Low	2007-11-01
Free Testosterone Test System	5325-300A 5325-300B	5375-300A 5375-300B			12.05.01.10.00	Low	2010-06-29
Thyroid							
Total Triiodothyronine (tT3) Test System	125-300A 125-300B 125-300D 125-300E	175-300A 175-300B 175-300D 175-300E			12.04.01.05.00	Low	2005-11-11
Free Triiodothyronine (fT3) Test System	1325-300A 1325-300B 1325-300A 1325-300B	1375-300A 1375-300B 1375-300D 1375-300E			12.04.01.01.00	Low	2005-11-11
Total Triiodothyronine (tT3 SBS) Test System	8125-300A 8125-300B	8175-300A 8175-300B			12.04.01.01.00	Low	2010-06-29
Rapid Total Triiodothyronine (Rapid -tT3) Test System	11225-300A 11225-300B				12.04.01.01.00	Low	2017-07-05
T3-Uptake (T3U) Test System	525-300A 525-300B	575-300A 575-300B			12.04.01.06.00	Low	2005-11-11
Thyroxine (tT4) Test System	225-300A 225-300B 225-300D 225-300E	275-300A 275-300B 275-300D 275-300E			12.04.01.07.00	Low	2005-11-11
Free Thyroxine (fT4) Test System	1225-300A 1225-300B 1225-300D 1225-300E	1275-300A 1275-300B 1275-300D 1275-300E			12.04.01.02.00	Low	2005-11-11
Total Thyroxine (tT4 SBS) Test System	8225-300A 8225-300B	8275-300A 8275-300B			12.04.01.01.00	Low	2010-06-29
Rapid Total Thyroxine (Rapid -tT4) Test System	11125-300A 11125-300B				12.04.01.01.00	Low	2017-07-05
Thyrotropin (TSH) Test System	325-300A 325-300B 325-300D 325-300E	375-300A 375-300B 375-300D 375-300E			12.04.01.11.00	Low	2005-11-11
Rapid TSH Test System	6025-300A 6025-300B	6075-300A 6075-300B			12.04.01.11.00	Low	2010-06-29
Thyroxine-Binding Globulin (TBG) Test System	3525-300A 3525-300B	3575-300A 3575-300B			12.04.01.09.00	Low	2005-11-11
Thyroglobulin (Tg) Test System	2225-300A	2275-300A			12.04.01.08.00	Low	2005-11-11

<i>Device types</i>	<i>Item# AccuBind® ELISA Microwells</i>	<i>Item# AccuLite® CLIA Microwells</i>	<i>Item# QSure® Control</i>	<i>Item# Instru- ment</i>	<i>EDMS code</i>	<i>Risk Class</i>	<i>First date of CE-marking</i>
	2225-300B	2275-300B					
Total Thyroxine (tT4), Total Triiodothyronine (tT3) & Thyroid Stimulating Hormone (TSH) (Thyroid Panel VAST) Test System	8025-300B 8025-300D 8025-300E	8075-300B 8075-300D 8075-300E			12.04.01.01.00	Low	2005-11-11
Free Thyroxine (fT4), Free Triiodothyronine (fT3) & Thyroid Stimulating Hormone (TSH) (Free Thyroid Panel VAST) Test System	7025-300B 7025-300D 7025-300E	7075-300B 7075-300D 7075-300E			12.04.01.01.00	Low	2010-06-29

Miscellaneous Controls							
Anti-H. Pylori Control (IgA, IgG, IgM) – Positive & Negative			HPC-300		12.50.01.16.00	Low	2013-09-16
Anti-Tg & Anti-TPO Control – Positive & Negative			AIT-101		12.50.01.16.00	Low	2010-06-29
Maternal Control – (AFP, uE3, hCG, Free beta hCG) Tri Level			MC-300		12.50.01.16.00	Low	2010-06-29
TBG Control – Tri-Level			TBG-300		12.50.01.16.00	Low	2013-09-16
Tg Control – Tri-Level			TG-300		12.50.01.16.00	Low	2010-06-29
Tumor Marker Control – (CA 125, CA 15-3, CA 19-9) Tri-Level			TMC-300		12.50.01.16.00	Low	2013-09-16

Miscellaneous Instruments							
Autoplex® ELISA & CLIA Analyzer				IN006	21.02.10.01	Low	2010-06-29
Autoplex® G2 ELISA & CLIA Analyzer				IN006-2	21.02.10.01	Low	2013-09-16
Autoplex® G3 ELISA & CLIA Analyzer				IN006-3	21.02.10.01	Low	2017-07-05
NeoEldex® ELISA Analyzer				IN009	21.02.10.01	Low	2011-09-26
Impulse® 3 CLIA Analyzer				IN007	21.02.10.01	Low	2010-06-29
NeoLumax® CLIA Analyzer				IN010	21.02.10.01	Low	2011-09-26
LuMatic® CLIA Analyzer				IN008	21.02.10.01	Low	2011-09-26
PrisMatic® ELISA Analyzer				IN013	21.02.10.01	Low	2013-09-16
PlateWash - Immunoassay Washer				IN002	21.02.10.01	Low	2010-06-29
TITIN® ELISA & CLIA Analyzer				IN015-EC	21.02.10.01	Low	2017-07-05
TITIN® ELISA Analyzer				IN015-E	21.02.10.01	Low	2017-07-05
TITIN-s® ELISA & CLIA Analyzer				IN016-EC	21.02.10.01	Low	2017-07-05
TITIN-s® ELISA Analyzer				IN016-E	21.02.10.01	Low	2017-07-05



Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Certificate No. 3868-7-2011

CERTIFICATE TO FOREIGN GOVERNMENT

In order to allow the importation of United States products into foreign countries, the U.S. Food and Drug Administration (FDA) certifies the following information concerning the product(s) to be exported listed below:

Name of Product(s)

Name of Manufacturer/Distributor Address

See Attached List
(Two Pages)

Manufacturer:
Monobind, Inc.
100 North Pointe Drive
Lake Forest, CA 92630.

Distributor:
Monobind, Inc.
100 North Pointe Drive
Lake Forest, CA 92630.

The product(s) described above (and the manufacturing/distribution site(s) which produces/distributes it) is subject to the jurisdiction of the FDA under the Federal Food, Drug, and Cosmetic Act.

It is certified that the above product(s) may be marketed in, and legally exported from, the United States of America at this time. The manufacturing plant(s) in which the product(s) is produced is subject to periodic inspections. The last such inspection showed that the plant(s), at that time, appeared to be in substantial compliance with current good manufacturing practice requirements for the products(s) listed above.

Ann M. Ferriter
Acting Director
Division of Risk Management Operations
Office of Compliance
Center for Devices and Radiological Health

This certificate expires 24 months from the date notarized.

COUNTY OF MONTGOMERY
STATE OF MARYLAND

Subscribed and sworn to before me this 10 day of Aug month 2011 year.

CATHRYN N. MORRIS
NOTARY PUBLIC STATE OF MARYLAND
County of Montgomery
My Commission Expires January 4, 2013



Certificate to Foreign Government – Attachment (Page 1 of 2)

NAME OF PRODUCT(S)

**NAME OF MANUFACTURER/DISTRIBUTOR,
ADDRESS**

Total T3 TEST SYSTEM
Total T4 TEST SYSTEM
Free T4 TEST SYSTEM
Free T3 TEST SYSTEM
TSH TEST SYSTEM
T3 Uptake TEST SYSTEM
TBG TEST SYSTEM
Tg TEST SYSTEM
N-T4 TEST SYSTEM
N-TSH TEST SYSTEM
N-17-OHP TEST SYSTEM
Anti-Tg TEST SYSTEM
Anti-TPO TEST SYSTEM
LH TEST SYSTEM
FSH TEST SYSTEM
PRL TEST SYSTEM
HCG TEST SYSTEM
Cortisol TEST SYSTEM
Testosterone TEST SYSTEM
Free Testosterone TEST SYSTEM
Progesterone TEST SYSTEM
17-OH Progesterone TEST SYSTEM
Estradiol TEST SYSTEM
Estriol TEST SYSTEM
DHEA-S TEST SYSTEM
DHEA TEST SYSTEM
HGH TEST SYSTEM
Insulin TEST SYSTEM
C-Peptide TEST SYSTEM
IgE TEST SYSTEM
Ferritin TEST SYSTEM
Transferrin Soluble Receptor TEST SYSTEM
Vit B12 TEST SYSTEM
Folate TEST SYSTEM
Creatine Kinase TEST SYSTEM
Digoxin TEST SYSTEM
hsCRP TEST SYSTEM
Myoglobin TEST SYSTEM
cTnl TEST SYSTEM
H. Pylori Ab TEST SYSTEM
HbSAg TEST SYSTEM

Manufacturer:
Monobind Inc.,
100 North Pointe Drive
Lake Forest, CA 92630.



Certificate to Foreign Government – Attachment (Page 2 of 2)

NAME OF PRODUCT(S)

**NAME OF MANUFACTURER/DISTRIBUTOR,
ADDRESS**

Rubella TEST SYSTEM
Toxoplasma TEST SYSTEM
AFP TEST SYSTEM
CEA TEST SYSTEM
tPSA TEST SYSTEM
fPSA TEST SYSTEM
CA-125 TEST SYSTEM
CA-19-9 TEST SYSTEM
CA-15-3 TEST SYSTEM
Free Beta hCG TEST SYSTEM
Mult-Ligand Quality Control Material
Cardiac Panel Quality Control Material
Tumor Marker Quality Control Material
Thyroid Panel Quality Control Material
Fertility Quality Control Material

Manufacturer:
Monobind Inc.,
100 North Pointe Drive
Lake Forest, CA 92630

**TEST SYSTEMS available in ELISA (AccuBind®), CLIA (AccuLite®) and VAST® formats.
Quality Control Material available in (QSure®) Assayed and Unassayed formats.**

Lumax® CLIA Analyzer
NeoLumax™ CLIA Analyzer
LuMatic™ CLIA Analyzer
Lumax-96™ CLIA Analyzer
Impulse 2™ CLIA Analyzer
Impulse3™ CLIA Analyzer
Eldex 3.8® ELISA Analyzer
NeoEldex™ ELISA Analyzer
Autoplex™ ELISA & CLIA Analyzer
Immunoassay Plate Washer

Distributor:
Monobind Inc.
100 North Pointe Drive
Lake Forest, CA 92630

“END OF PRODUCT LIST”





NSAI

Certificate of Registration of Quality Management System to I.S. EN ISO 13485:2016

The National Standards Authority of Ireland certifies that:

Monobind Inc.
100 North Pointe Drive
Lake Forest, CA 92630
USA

has been assessed and deemed to comply with the requirements of the above standard in respect of the scope of operations given below:

The Design, Manufacture and Distribution of In-Vitro Diagnostic Medical Device Immunoassays and Related Reagents, Controls, and Semi-Manual and Automated Washers and Analyzers.

Additional sites covered under this multi-site certification are listed on the Annex (File No. MD19.4585)

Approved by:
Geraldine Larkin
Chief Executive Officer

Approved by:
Caroline Dore Geraghty
Director of Medical Devices /
Head of Notified Body

Registration Number: MD19.4585
Certification Granted: May 18, 2010
Effective Date: September 25, 2019
Expiry Date: September 24, 2022





NSAI

Annex to Certificate Number: MD19.4585

Scope of Registration:

The Design, Manufacture and Distribution of In-Vitro Diagnostic Medical Device Immunoassays and Related Reagents, Controls, and Semi-Manual and Automated Washers and Analyzers.

Activity

Location

Headquarters, Administration,
Design, Manufacturing,
Distribution

Monobind Inc.
100 North Pointe Drive
Lake Forest, CA 92630
USA
File No.: MD19.4585

Manufacturing, Distribution

Monobind Inc.
103 North Pointe Drive
Lake Forest, CA 92630
USA
File No.: MD19.4585/A

**Verified by:
Operations Manager**

ORGENTEC Diagnostika GmbH


Carl-Zeiss-Straße 49-51

55129 Mainz - Germany

Phone: +49 (0) 61 31 / 92 58-0

Fax: +49 (0) 61 31 / 92 58-58

Internet: www.orgentec.com



ORG 515 Anti-Cardiolipin IgG/IgM

INTENDED PURPOSE

Anti-Cardiolipin IgG/IgM is an ELISA test system for the quantitative measurement of IgG and IgM class autoantibodies against cardiolipin in human serum or plasma. This product is intended for professional in vitro diagnostic use only.

Antiphospholipid syndrome (APS, Hughes Syndrome) is a systemic autoimmune disease that causes thromboses, recurrent miscarriage or stillbirths, and stroke. Clinical symptoms are accompanied by specific autoantibodies in the blood, which bind to phospholipids like cardiolipin, or phospholipid-binding proteins like beta-2-glycoprotein I. Autoantibodies against proteins of the coagulation cascade, e.g. prothrombin or annexin V may also be found in patients with APS with otherwise negative phospholipid antibody results. In primary APS autoantibodies against phospholipids appear independently, while in secondary APS phospholipid antibodies are detected in conjunction with other autoimmune diseases, such as lupus erythematosus, rheumatoid arthritis, or Sjögren's syndrome.

SYMBOLS USED ON LABELS

In vitro diagnostic medical device

Manufacturer

Catalogue number

Sufficient for 96 determinations

Batch code

Use by

Temperature limitation

Keep away from sunlight

Do not reuse

Date of manufacture

CE marked according to 98/79/EC

Consult instructions for use

Electronic Instruction For Use: version

Microplate

Calibrator

Calibrator

Calibrator

Calibrator

Calibrator

Calibrator

Control positive

Control negative

Sample Buffer P

Enzyme Conjugate

Enzyme Conjugate

TMB Substrate

Stop solution

Wash Buffer

Ready to use

PRINCIPLE OF THE TEST

Highly purified cardiolipin is coated on microwells saturated with beta-2-glycoprotein I.

The determination is based on an indirect enzyme linked immune reaction with the following steps:

Specific antibodies in the patient sample bind to the antigen coated on the surface of the reaction wells. After incubation, a washing step removes unbound and unspecifically bound serum or plasma components. Subsequently added enzyme conjugate binds to the immobilized antibody-antigen-complexes. After incubation, a second washing step removes unbound enzyme conjugate. After addition of substrate solution the bound enzyme conjugate hydrolyses the substrate forming a blue coloured product. Addition of an acid stops the reaction generating a yellow end-product. The intensity of the yellow color correlates with the concentration of the antibody-antigen-complex and can be measured photometrically at 450 nm.

WARNINGS AND PRECAUTIONS


















- All reagents of this kit are intended for professional in vitro diagnostic use only.
- Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
- Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
- Avoid contact with the substrate TMB (3,3',5,5'-Tetramethyl-benzidine).
- Stop solution contains acid, classification is non-hazardous. Avoid contact with skin.
- Control, sample buffer and wash buffer contain sodium azide 0.09% as preservative. This concentration is classified as non-hazardous.
- Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.

During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:

- First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin, wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running water for at least 10 minutes. Get medical attention if necessary.
- Personal precautions, protective equipment and emergency procedures:
Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.
- Exposure controls / personal protection: Wear protective gloves of nitril rubber or natural latex. Wear protective glasses. Used according to intended use no dangerous reactions known.
- Conditions to avoid: Since substrate solution is light-sensitive. Store in the dark.
- For disposal of laboratory waste the national or regional legislation has to be observed.

Observe the guidelines for performing quality control in medical laboratories by assaying control sera.

CONTENTS OF THE KIT

ORG 515		96	Sufficient for 96 determinations
	1		One divisible microplate consisting of 12 modules of 8 wells each. Ready to use. Product code on module: CLP
	1x 1.5 ml		Calibrator A 0 GPL-U/ml / 0 MPL-U/ml, containing serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
	1x 1.5 ml		Calibrator B 7.5 GPL-U/ml / 5 MPL-U/ml, containing Cardiolipin antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
	1x 1.5 ml		Calibrator C 15 GPL-U/ml / 10 MPL-U/ml, containing Cardiolipin antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
	1x 1.5 ml		Calibrator D 30 GPL-U/ml / 20 MPL-U/ml, containing Cardiolipin antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
	1x 1.5 ml		Calibrator E 60 GPL-U/ml / 40 MPL-U/ml, containing Cardiolipin antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
	1x 1.5 ml		Calibrator F 120 GPL-U/ml / 80 MPL-U/ml, containing Cardiolipin antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
	1x 1.5 ml		Control positive, containing cardiolipin antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.
	1x 1.5 ml		Control negative, containing cardiolipin antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.
	20 ml		Sample Buffer P; containing PBS, BSA, detergent, preservative sodium azide 0.09%, yellow, concentrate 5x.
	15 ml		Enzyme Conjugate IgG; containing anti-human IgG antibodies, HRP labelled; PBS, BSA, detergent, preservative PROCLIN 0.05%, light red. Ready to use.
	15 ml		Enzyme Conjugate IgM; containing anti-human IgM antibodies, HRP labelled; PBS, BSA, detergent, preservative PROCLIN 0.05%, light red. Ready to use.
	15 ml		TMB Substrate, containing 3,3', 5,5'- Tetramethylbenzidin. Ready to use.
	15 ml		Stop solution; contains acid. Ready to use.
	20 ml		Wash Buffer, containing Tris, detergent, preservative sodium azide 0.09%; 50 x conc.
	1		Certificate of Analysis

MATERIALS REQUIRED

- Microplate reader capable of endpoint measurements at 450 nm; optional: reference filter at 620 nm
- Data reduction software
- Multi-channel dispenser or repeatable pipette for 100 µl
- Vortex mixer
- Pipettes for 10 µl, 100 µl and 1000 µl
- Laboratory timing device
- Distilled or deionised water
- Measuring cylinder for 1000 ml and 100 ml
- Plastic container for storage of the wash solution

This ELISA assay is suitable for use on open automated ELISA processors. Each assay has to be validated on the respective automated system. Detailed information is provided upon request.

SPECIMEN COLLECTION, STORAGE AND HANDLING

- Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months.
- Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
- Testing of heat-inactivated sera is not recommended.

STORAGE AND STABILITY

- Store test kit at 2-8°C in the dark.
- Do not expose reagents to heat, sun, or strong light during storage and usage.
- Store microplate sealed and desiccated in the clip bag provided.
- Shelf life of the unopened test kit is 18 months from day of production.
Unopened reagents are stable until expiration of the kit. See labels for individual batch.
- Diluted Wash Buffer and Sample Buffer are stable for at least 30 days when stored at 2-8°C.
We recommend consumption on the same day.

PROCEDURAL NOTES

- Do not use kit components beyond their expiration dates.
- Do not interchange kit components from different lots and products.
- All materials must be at room temperature (20-28°C) prior to use.
- Prepare all reagents and samples. Once started, perform the test without interruption.
- Double determinations may be done. By this means pipetting errors may become obvious.
- Perform the assay steps only in the order indicated.
- Always use fresh sample dilutions.
- Pipette all reagents and samples into the bottom of the wells.
- To avoid carryover or contamination, change the pipette tip between samples and different kit controls.
- Wash microwells thoroughly and remove the last droplets of wash buffer.
- All incubation steps must be accurately timed.
- Do not re-use microplate wells.

PREPARATION OF REAGENTS

WASH

Dilute the contents of one vial of the buffered wash solution concentrate (50x) with distilled or deionised water to a final volume of 1000 ml prior to use.

DILUENT

Sample Buffer P: Prior to use dilute the contents (20 ml) of one vial of sample buffer 5x concentrate with distilled or deionised water to a final volume of 100 ml.

Preparation of samples

Dilute patient samples 1:100 before the assay: Put 990 µl of prediluted sample buffer in a polystyrene tube and add 10 µl of sample. Mix well. Note: Calibrators / Controls are ready to use and need not be diluted.

TEST PROCEDURE

Prepare enough microplate modules for all calibrators / controls and patient samples.

- Pipette **100 µl** of calibrators, controls and prediluted patient samples into the wells.
Incubate for **30 minutes** at room temperature (20-28 °C).
Discard the contents of the microwells and **wash 3 times** with **300 µl** of wash solution.
- Dispense **100 µl** of enzyme conjugate into each well.
Incubate for **15 minutes** at room temperature.
Discard the contents of the microwells and **wash 3 times** with **300 µl** of wash solution.
- Dispense **100 µl** of TMB substrate solution into each well.
Incubate for **15 minutes** at room temperature
- Add 100 µl** of stop solution to each well of the modules
Incubate for **5 minutes** at room temperature.
Read the optical density at 450 nm (reference 600-690nm) and calculate the results.
The developed colour is stable for at least 30 minutes. Read during this time.

Example for a pipetting scheme:

	1	2	3	4	5	6	7	8	9	10	11	12
A	A	P1	A	P1								
B	B	P2	B	P2								
C	C	P3	C	P3								
D	D	P4	D	P4								
E	E	P5	E	P5								
F	F	P6	F	P6								
G	C+	P7	C+	P7								
H	C-	P8	C-	P8								

IgG IgG IgM IgM

P1, ... patient sample A-F calibrators C+, C- controls

VALIDATION

Test results are valid if the optical densities at 450 nm for calibrators / controls and the results for controls comply with the reference ranges indicated on the Certificate of Analysis enclosed in each test kit.

If these quality control criteria are not met the assay run is invalid and should be repeated.

CALCULATION OF RESULTS

For quantitative results plot the optical density of each calibrator versus the calibrator concentration to create a calibration curve. The concentration of patient samples may then be estimated from the calibration curve by interpolation.

Using data reduction software a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is the data reduction method of choice.

PERFORMANCE CHARACTERISTICS

Calibration

The assay system is calibrated against the internationally recognised reference sera from E.N. Harris, Louisville and the specific reference material IRP 97/656 (IgG) and HCAL (IgG) / EY2C9 (IgM).

Measuring range

The calculation range of this ELISA assay is IgG: 0 - 120 GPL-U/ml IgM: 0 - 80 MPL-U/ml

Expected values

In a normal range study with samples from healthy blood donors the following ranges have been established with this ELISA assay: Cut-off IgG: 10 GPL-U/ml IgM: 7 MPL-U/ml

Interpretation of results

Negative: IgG < 10 GPL-U/ml IgM < 7 MPL-U/ml
Positive: ≥ 10 GPL-U/ml ≥ 7 MPL-U/ml

Linearity

Patient samples containing high levels of specific antibody were serially diluted in sample buffer to demonstrate the dynamic range of the assay and the upper / lower end of linearity. Activity for each dilution was calculated from the calibration curve using a 4-Parameter-Fit with lin-log coordinates.

Sample	Dilution Factor	Observed	Expected	O/E [%]
		GPL/MPL-U/ml	GPL/MPL-U/ml	
IgG 1	1	73.0	73.0	100
	2	37.1	36.5	102
	4	19.6	18.3	107
	8	10.9	9.1	120
IgG 2	1	80.5	80.5	100
	2	42.0	40.3	104
	4	22.2	20.1	111
	8	12.1	10.1	120
IgG 3	1	66.2	64.4	103
	2	34.5	32.2	107
	4	16.2	16.1	101
	8	8.1	8.1	101
IgM 1	1	70.9	70.9	100
	2	34.1	35.5	96
	4	18.2	17.7	103
	8	10.1	8.9	114
IgM 2	1	114.0	114.0	100
	2	50.6	57.0	89
	4	27.3	28.5	96
	8	14.8	14.3	104
IgM 3	1	48.2	48.2	100
	2	24.7	24.1	102
	4	12.7	12.1	105
	8	7.1	6.0	118

Limit of detection

Functional sensitivity was determined to be: IgG: 1 GPL-U/ml IgM: 0.5 MPL-U/ml

Reproducibility

Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below.

Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 6 determinations in 5 different runs. Results for run-to-run precision are shown in the table below.

Intra-Assay IgG		
Sample	Mean GPL-U/ml	CV %
1	10.9	5.5
2	20.5	5.4
3	73.0	5.4

Inter-Assay IgG		
Sample	Mean GPL-U/ml	CV %
1	11.8	5.3
2	21.1	3.7
3	70.5	6.3

Intra-Assay IgM		
Sample	Mean MPL-U/ml	CV %
1	12.8	3.7
2	30.7	4.1
3	65.2	3.8

Inter-Assay IgM		
Sample	Mean MPL-U/ml	CV %
1	12.2	3.5
2	31.4	3.5
3	64.9	4.2

Interfering substances

No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic (up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparine). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

Study results

Study population	n	Pos IgG	%	Pos IgM	%
Primary APS	8	6	75.0	4	50.0
Secondary APS	65	57	87.7	26	40.0
Normal human serum	150	6	4.0	3	2.0

		Clinical Diagnosis		
		POS	NEG	
ORG 515	POS	63	6	223
IgG	NEG	10	144	
		73	150	
Sensitivity:		86.3 %		
Specificity:		96.0 %		
Overall agreement:		92.8 %		

		Clinical Diagnosis		
		Pos	Neg	
ORG 515	Pos	30	3	223
IgM	Neg	43	147	
		73	150	
Sensitivity:		41.1 %		
Specificity:		98.0 %		
Overall agreement:		79.4 %		

LIMITATIONS OF THE PROCEDURE

This assay is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but should be made by the physician after all clinical and laboratory findings have been evaluated concerning the entire clinical picture of the patient. Also every decision for therapy should be taken individually.

The above pathological and normal reference ranges for antibodies in patient samples should be regarded as recommendations only. Each laboratory should establish its own ranges according to ISO 15189 or other applicable laboratory guidelines.

REFERENCES

- Banzato A, Pozzi N, Frasson R, De F, V, Ruffatti A, Bison E et al. Antibodies to Domain I of beta(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). *Thromb Res* 2011; 128 (6):583-6.
- Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de LB, Forastiero R et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. *Lupus* 2011; 20(2):191-205.
- de Laat B, de Groot PG. Autoantibodies directed against domain I of beta2-glycoprotein I. *Curr Rheumatol Rep* 2011; 13(1):70-6.
- de Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. *Nat Clin Pract Rheumatol* 2008; 4(4):192-9.
- de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. *J Thromb Haemost* 2009; 7(11):1767-73.
- Espinosa G, Cervera R. Antiphospholipid syndrome. *Arthritis Res Ther* 2008; 10(6):230.
- Favaloro EJ, Wong RC. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. *Clin Chem Lab Med* 2011; 49(3):447-61.
- Fischer MJ, Rauch J, Levine JS. The antiphospholipid syndrome. *Arthritis Rheum* 2007; 27(1):35-46.
- Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. *Blood* 2009; 113(5):985-94.
- Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. *Br J Haematol* 2000; 109(4):704-15.
- Hughes GR. Hughes syndrome: antiphospholipid syndrome. *J R Coll Physicians Lond* 1998; 32(3):260-4.
- Hughes GR. Hughes Syndrome (the antiphospholipid syndrome): ten clinical lessons. *Autoimmun Rev* 2008; 7(3):262-6.
- Hughes GR. Antiphospholipid syndrome, migraine and stroke. *Lupus* 2010; 19(5):555-6.
- Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. *J Rheumatol* 1986; 13(3):486-9.

- Koike T, Bohgaki M, Amengual O, Atsumi T. Antiphospholipid antibodies: lessons from the bench. *J Autoimmun* 2007; 28(2-3):129-33.
- Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. *Arthritis Rheum* 2012; 64(1):1-10.
- Mackworth-Young C. Primary antiphospholipid syndrome: a distinct entity? *Autoimmun Rev* 2006; 5(1):70-5.
- Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 2006; 4(2):295-306.
- Molina JF, Gutierrez-Urena S, Molina J, Uribe O, Richards S, De CC et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. *J Rheumatol* 1997; 24(2):291-6.
- Oku K, Atsumi T, Amengual O, Koike T. Antiprothrombin antibody testing: detection and clinical utility. *Semin Thromb Hemost* 2008; 34(4):335-9.
- Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A. Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. *Thromb Res* 2007; 120(1):127-33.
- Pierangeli SS, de Groot PG, Dlott J, Favaloro E, Harris EN, Lakos G et al. 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. *Lupus* 2011; 20(2):182-90.
- Pierangeli SS, Favaloro EJ, Lakos G, Meroni PL, Tincani A, Wong RC et al. Standards and reference materials for the anticardiolipin and anti-beta-2-glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. *Clin Chim Acta* 2012; 413(1-2):358-60.
- Sinico RA, Bollini B, Sabadini E, Di Toma L, Radice A. The use of laboratory tests in diagnosis and monitoring of systemic lupus erythematosus. *J Nephrol JID - 9012268* 2002; 15 Suppl 6:S20-S27.
- Tincani A, Andreoli L, Casu C, Cattaneo R, Meroni P. Antiphospholipid antibody profile: implications for the evaluation and management of patients. *Lupus* 2010; 19(4):432-5.
- Tincani A, Morozzi G, Afeltra A, Alessandri C, Allegri F, Bistoni O et al. Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). *Clin Exp Rheumatol* 2007; 25(2):268-74.
- Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. *Arthritis Rheum* 1999; 42(7):1309-11.
- Wong RC, Favaloro EJ, Adelstein S, Baumgart K, Bird R, Brighton TA et al. Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. *Pathology* 2008; 40(1):58-63.
- Wong RC, Gillis D, Adelstein S, Baumgart K, Favaloro EJ, Hendle MJ et al. Consensus guidelines on anticardiolipin antibody testing and reporting. *Pathology* 2004; 36(1):63-8.

Notice to the user (European Union):

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the EU Member State in which the user and/or the patient is established .

Change Control

Former version: *ORG 515_IFU_EN_QM113142_2016-04-18_2*

Reason for revision: *Introduction electronic IFU on homepage*

- 1 Pipet **100 µl** calibrator, control or patient sample
 - Incubate for **30 minutes** at room temperature
 - Discard the contents of the wells and wash 3 times with **300 µl** wash solution
- 2 Pipet **100 µl** enzyme conjugate
 - Incubate for **15 minutes** at room temperature
 - Discard the contents of the wells and wash 3 times with **300 µl** wash solution
- 3 Pipet **100 µl** substrate solution
 - Incubate for **15 minutes** at room temperature
- 4 Add **100 µl** stop solution
 - Leave untouched for **5 minutes**
 - Read at **450 nm**

Certificate

mdc medical device certification GmbH
certifies that

ORGENTEC Diagnostika GmbH
Carl-Zeiss-Straße 49 - 51
55129 Mainz
Germany

with the locations listed in the attachment

for the scope

**design, development, manufacturing and distribution of
in-vitro diagnostic test kits, reagents, controls and analyzers/instruments used
in the diagnosis of autoimmune and infectious diseases**

has introduced and applies a

Quality Management System

The mdc audit has proven that this quality management system
meets all requirements of the following standard

EN ISO 13485

Medical devices – Quality management systems –
Requirements for regulatory purposes

EN ISO 13485:2016 + AC:2016 - ISO 13485:2016

Valid from	2019-04-01
Valid until	2022-03-31
Registration no.	D1227900020
Report no.	P18-01487-133131
Stuttgart	2019-04-01



Head of Certification Body



Attachment of the certificate

No. D1227900020

date 2019-04-01

Page 1 of 1

Location	Scope
ORGENTEC Diagnostika GmbH Carl-Zeiss-Straße 49 – 51 55129 Mainz Germany	design, development, manufacturing and distribution of in-vitro diagnostic test kits, reagents, controls and analyzers/instruments used in the diagnosis of autoimmune and infectious diseases
ORGENTEC Austria GmbH Hausfeldstraße 90 A2232 Deutsch-Wagram Austria	distribution of in-vitro diagnostic test kits, reagents, controls and analyzers/instruments used in the diagnosis of autoimmune and infectious diseases
ORGENTEC Hungary Kft. Aradi Vértanúk utca 45 H2060 Bicske Hungary	distribution of in-vitro diagnostic test kits, reagents, controls and analyzers/instruments used in the diagnosis of autoimmune and infectious diseases



Head of Certification Body

MANAGEMENT SYSTEM CERTIFICATE

Certificate no.:
59878-2009-AQ-MCW-FINAS

Initial certification date:
20 December 2000

Valid:
01 September 2021 – 31 August 2024

This is to certify that the management system of
THERMO FISHER SCIENTIFIC
Kubinskaya 73, liter A, build.1, Saint-Petersburg, Russian Federation, 196240

has been found to conform to the Quality Management System standard:
ISO 9001:2015

This certificate is valid for the following scope:
**MANUFACTURING OF LIQUID HANDLING PRODUCTS AND SPECIAL DIAGNOSTIC
PLASTICS.**

Place and date:
Espoo, 18 June 2021



For the issuing office:
DNV - Business Assurance
Keilaranta 1, 02150 Espoo, Finland



Kimmo Haarala
Management Representative



ФЕДЕРАЛЬНАЯ СЛУЖБА ПО НАДЗОРУ В СФЕРЕ ЗДРАВООХРАНЕНИЯ
И СОЦИАЛЬНОГО РАЗВИТИЯ

РЕГИСТРАЦИОННОЕ УДОСТОВЕРЕНИЕ

№ ФСР 2009/05681

от 15 сентября 2009 года

Срок действия: не ограничен.

Настоящее удостоверение выдано

ЗАО "Термо Фишер Сайентифик",
Россия, 196240, Санкт-Петербург, ул. Кубинская, д.73, корпус 1, лит.А

и подтверждает, что изделие медицинского назначения
(изделие медицинской техники)

Дозаторы пипеточные, одно- и многоканальные, "Блэк"
по ТУ 9443-008-33189998-2009

производства

ЗАО "Термо Фишер Сайентифик",
Россия, 196240, Санкт-Петербург, ул. Кубинская, д.73, корпус 1, лит.А

класс потенциального риска 2а

ОКП 94 4370

соответствующее комплекту регистрационной документации

КРД № 33014 от 09.07.2009

приказом Росздравнадзора от 15 сентября 2009 года № 7252-Пр/09

разрешено к производству, продаже и применению на территории Российской Федерации

**Руководитель Федеральной службы
по надзору в сфере здравоохранения
и социального развития**



Н.В. Юргель

006376